Ixekizumab
- Generic Name
- Ixekizumab
- Brand Names
- Taltz
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1143503-69-8
- Unique Ingredient Identifier
- BTY153760O
- Background
Ixekizumab is a humanized immunoglobulin G subclass 4 (IgG4) monoclonal antibody (mAb) against interleukin-17A (IL-17A) and prevents it from interacting with the IL-17A receptor. As IL-17A is a pro-inflammatory cytokine involved in inflammation and immune responses, blocking its effect is beneficial for use in inflammatory conditions. In particular, IL-17A h...
- Indication
Ixekizumab is indicated for the treatment of patients aged six years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. It is also indicated in adult patients with active psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis with objective signs of inflammation.
- Associated Conditions
- Moderate to Severe Plaque Psoriasis, Active Ankylosing spondylitis, Active Non-radiographic Axial Spondyloarthritis, Active Psoriatic arthritis
- Associated Therapies
- -
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588296
- Locations
- 🇺🇸
Willow Rheumatology and Wellness PLLC, Willowbrook, Illinois, United States
🇺🇸Research Physicians Network, LLC, Houston, Texas, United States
🇺🇸Biopharma Informatic, LLC, Katy, Texas, United States
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT06588283
- Locations
- 🇺🇸
NeoClinical Research, Hialeah, Florida, United States
🇺🇸Skin Care Research, Hollywood, Florida, United States
🇺🇸Encore Medical Research, Hollywood, Florida, United States
A Study of Ixekizumab (LY2439821) in Participants Aged ≥18 Years With Moderate-to-Severe Plaque or Active Psoriatic Arthritis in India
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 250
- Registration Number
- NCT05855967
- Locations
- 🇮🇳
Oyster & Pearl Hospitals (Phadnis Clinic Pvt. Ltd.), Pune, Maharashtra, India
🇮🇳Postgraduate Institute of Medical Education & Research, Chandigarh, Punjab, India
🇮🇳Wizderm Specialty Skin And Hair Clinic, Kolkata, West Bengal, India
COVID-19 VaccinE Response in Rheumatology Patients
- First Posted Date
- 2021-10-15
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Jeffrey Curtis
- Target Recruit Count
- 1000
- Registration Number
- NCT05080218
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
🇺🇸Arizona Arthritis & Rheumatology Research, PLLC, Phoenix, Arizona, United States
🇺🇸University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States
Targeting IL-17A for Treatment-Resistant Depression
- First Posted Date
- 2021-07-28
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 20
- Registration Number
- NCT04979910
- Locations
- 🇺🇸
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-10-30
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 270
- Registration Number
- NCT04610476
- Locations
- 🇩🇪
Universitätsklinikum Erlangen, Erlangen, Bavaria, Germany
Ixekizumab Diabetes Intervention Trial (I-DIT)
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Göteborg University
- Target Recruit Count
- 127
- Registration Number
- NCT04589325
- Locations
- 🇸🇪
Länssjukhuset Ryhov, Jönköping, Sweden
🇸🇪Skaraborgs sjukhus, Skövde, Sweden
🇸🇪Varbergs sjukhus, Varberg, Sweden
A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
- Conditions
- Interventions
- First Posted Date
- 2020-08-26
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 100
- Registration Number
- NCT04527380
- Locations
- 🇬🇧
Sheffield Children's Hospital, Sheffield, United Kingdom
🇬🇧Alder Hey Children's Hospital, Liverpool, England, United Kingdom
🇬🇧Oxford University Hospitals - Nuffield Orthopaedic Centre, Oxford, Oxfordshire, United Kingdom
Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Conditions
- Interventions
- First Posted Date
- 2020-04-09
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Radboud University Medical Center
- Target Recruit Count
- 244
- Registration Number
- NCT04340076
- Locations
- 🇳🇱
Amphia Hospital, Breda, Netherlands
🇳🇱Radboudumc, Nijmegen, Netherlands
🇳🇱Máxima Medisch Centrum, Veldhoven, Netherlands
A Study of Ixekizumab (LY2439821) in Chinese Participants With Radiographic Axial Spondyloarthritis
- First Posted Date
- 2020-02-26
- Last Posted Date
- 2023-04-14
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 147
- Registration Number
- NCT04285229
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
🇨🇳1st Hospital affiliated to Medical College of Shantou Univer, Shantou, Guangzhou, China
🇨🇳People's Hospital of Xinjiang Uygur Autonomous Region, Urumqi, Xinjiang, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.